(Q39885291)

15 September 2017

title

Evolution of clinical trials for irritable bowel syndrome: issues in end points and study design (English)

1 reference

15 September 2017

main subject

irritable bowel syndrome

1 reference

based on heuristic

inferred from title

author name string

Ann Marie Trentacosti

1

1 reference

15 September 2017

Ruyi He

2

1 reference

15 September 2017

Laurie B Burke

3

1 reference

15 September 2017

Donna Griebel

4

1 reference

15 September 2017

Dianne L Kennedy

5

1 reference

15 September 2017

language of work or name

English

0 references

publication date

1 April 2010

1 reference

The American Journal of Gastroenterology

15 September 2017

published in

1 reference

15 September 2017

volume

105

1 reference

15 September 2017

issue

4

1 reference

15 September 2017

page(s)

731-735

1 reference

Functional GI disorders: from animal models to drug development

15 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.12

Pathophysiology as a basis for understanding symptom complexes and therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.12

Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.12

Defecation frequency and timing, and stool form in the general population: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.12

Gastrointestinal transit abnormalities are frequently detected in patients with unexplained GI symptoms at a tertiary centre.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.12

Effect of a tricyclic antidepressant on small intestinal motility in health and diarrhea-predominant irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.12

Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.12

Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.12

Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.12

Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.12

A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.12

Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.12

A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.12

An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.12

A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.12

Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.12

A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.12

Tegaserod is safe, well tolerated and effective in the treatment of patients with non-diarrhoea irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.12

A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.12

Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.12

Subject's Global Assessment of Relief: an appropriate method to assess the impact of treatment on irritable bowel syndrome-related symptoms in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.12

Green light from the FDA for new drug development in irritable bowel syndrome and functional dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.12

Functional bowel disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.12

Review article: the safety and efficacy of alosetron, a 5-HT3 receptor antagonist, in female irritable bowel syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.12

Stool form scale as a useful guide to intestinal transit time

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.12

Core outcome domains for chronic pain clinical trials: IMMPACT recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.12

Core outcome measures for chronic pain clinical trials: IMMPACT recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.12

21 January 2018

Identifiers

DOI

10.1038/AJG.2010.12

1 reference

15 September 2017

1 reference